Work

Pathophysiology of Skeletal Disease

Year: 2022
Type: dissertation
Abstract: These studies have resulted in substantial advances in the field of osteoporosis and osteoarthritis \nresearch. Crucial contributions to pivotal osteoporosis GWAS identified 518 bone mineral density \nand 13 fracture loci that now account for over 20% of the population variance in bone density. We \nidentified over 300 novel eBMD loci and validated numerous genes, including (i) transferrin \nreceptor-2 as a novel regulator of bone mass acting via BMP/p38MAPK/Wnt signalling, (ii) over \n100 genes that determine bone mass, quality and strength comprising enzymes, ion and amino \nacid transporters, cell cycle regulators, transcription factors and modulators of non-canonical Wnt \nsignalling, and (iii) age-specific and sexually dimorphic genetic effects on bone mineral density. \nRecent discoveries include (i) identification of a new cell type with a unique transcriptome, termed \nthe “osteomorph”. Bone resorbing multinucleated osteoclasts undergo cycles of cell fission and \nfusion, recycling via osteomorphs in the bone marrow to regulate osteoclast motility and dynamic \nbone remodelling in vivo, (ii) elucidation of a transcriptome map of genes expressed in \nosteocytes, the master regulatory cells in bone. Osteocyte signature genes correlate closely with \nloci identified in human GWAS and in the nosology of monogenic skeletal disorders, establishing \nthe cellular pathogenesis of various skeletal diseases, and (iii) development of novel imaging \nmethods in osteoarthritis disease models and generation of the first multi ‘omic molecular QTL \nmap of human disease to accelerate causative gene discovery in osteoarthritis. This \nmultidisciplinary and international approach is transformative and has resulted in a \ncomprehensive atlas of human and murine genetic influences on bone and joint disease that offer \nnovel insights into the pathophysiology of osteoporosis and osteoarthritis with exciting \nopportunities for biomarker discovery and drug development. This body of work has resulted in \ninvitations to contribute seminal chapters in major international textbooks, including (i) Genetics of \nBone Biology and Skeletal Disease (2018) and (ii) Osteoporosis (2020), and Plenary Lectures to \nthe (i) 21st World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (IOFESCEO WCO), (ii) ASBMR Bone Turnover Markers Annual Meeting, and (iii) 9th Congress of the \nRomanian Society of Osteoporosis and Musculoskeletal Diseases (all in 2021). My work was \nrecognised by the European Calcified Tissue Society Steven Boonen Clinical Research Award \n(2018), and I was elected Fellow of the Academy of Medical Sciences (2019), Member of \nAcademia Europaea (2021) and Fellow of the Association of Physicians of Great Britain & Ireland \n(2021).
Language: English
Open Access status: green
OpenAlex ID: W7023717412
Cites:
Cited by:
Related to: 10